Abstract session: NAFLD - Clinical except therapy

 Metabolism, alcohol and toxicity

Room 3
English
Abstract session
27 August 2020 15:30 - 17:00


Presentations

Title Time

Add to Calendar

AS157 Liver disease progression and clinical outcomes in Hepatic Outcomes and Survival Fatty liver Registry (HOTSURFR) Study
27 August 2020 15:30 - 15:45
AS158 Causes of death in patients with nonalcoholic fatty liver disease (NAFLD): data from national vital statistics system (NVSS)
27 August 2020 15:45 - 16:00
AS159 A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD
27 August 2020 16:00 - 16:15
AS160 A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors
27 August 2020 16:15 - 16:30
AS161

Active Non-alcoholic Steatohepatitis and severe fibrosis are associated to dysfunctional adipose tissue and worsen with adipose tissue insulin resistance independently of Body Mass Index


27 August 2020 16:30 - 16:45
AS162 The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world
27 August 2020 16:45 - 17:00